Advertisement

Intensive Care Medicine

, Volume 44, Issue 9, pp 1536–1538 | Cite as

Understanding thrombotic microangiopathies in children

  • Bérangère S. Joly
  • X. Long Zheng
  • Agnès VeyradierEmail author
Understanding the Disease
Thrombotic microangiopathy (TMA) is an ultra-rare syndrome. The incidence in children is estimated to be ~ 3.0 cases/10 6 population per year (Fig.  1). Very importantly, TMA belongs to the Thrombocytopenia Associated-Multi Organ Failure (TAMOF) syndromes and, therefore, its diagnosis should be considered in critically-ill children. Thus, intensive care physicians and nurses should be familiar with this rare but specific cause of TAMOF. TMA is life-threatening, resulting from ischemic multi-organ failure and characterised by its diversity and high ICU mortality rate, ~ 20%, despite appropriate treatment [ 1, 2]. The common features for TMA are microangiopathic haemolytic anemia (haemolysis, elevated lactate dehydrogenase, reduced haptoglobin, and fragmentation of red blood cells) and thrombocytopenia. Organ injury, associated with disseminated thrombi in the microcirculation, further supports the diagnosis of TMA. Differential diagnosis includes idiopathic thrombocytopenic purpura (ITP),...

Notes

Compliance with ethical standards

Conflicts of interest

BSJ is recipient of the MaRIH research grant Alexion 2016; AV is a member of the French Advisory board on Caplacizumab (Ablynx); XLZ is a consultant for Ablynx and a member of the speakers’ bureau for Alexion.

References

  1. 1.
    George JN, Nester CM (2014) Syndromes of thrombotic microangiopathy. N Engl J Med 371:654–666CrossRefPubMedGoogle Scholar
  2. 2.
    George JN, Al-Nouri ZL (2012) Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes. Am Soc Hematol Educ Progr 2012:604–609Google Scholar
  3. 3.
    Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589–600CrossRefPubMedGoogle Scholar
  4. 4.
    Scully M, Cataland S, Coppo P et al (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15:312–322CrossRefPubMedGoogle Scholar
  5. 5.
    Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676–1687CrossRefPubMedGoogle Scholar
  6. 6.
    Fakhouri F, Zuber J, Frémeaux-Bacchi V et al (2017) Haemolytic uraemic syndrome. Lancet 390:681–696CrossRefPubMedGoogle Scholar
  7. 7.
    Grangé S, Bekri S, Artaud-Macari E et al (2015) Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet 386:1011–1012CrossRefPubMedGoogle Scholar
  8. 8.
    Zuber J, Fakhouri F, Roumenina LT et al (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643–657CrossRefPubMedGoogle Scholar
  9. 9.
    Licht C, Ardissino G, Ariceta G et al (2015) The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol 16:207CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Noris M, Caprioli J, Bresin E et al (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844–1859CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Joly BS, Coppo P, Veyradier A (2017) Thrombotic thrombocytopenic purpura. Blood 129:2836–2846CrossRefPubMedGoogle Scholar
  12. 12.
    Saha M, McDaniel JK, Zheng XL (2017) Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapies. J Thromb Haemost 15:1889–1900CrossRefPubMedGoogle Scholar
  13. 13.
    Furlan M, Robles R, Galbusera M et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584CrossRefPubMedGoogle Scholar
  14. 14.
    Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Levy GG, Nichols WC, Lian EC et al (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494CrossRefPubMedGoogle Scholar
  16. 16.
    Joly BS, Stepanian A, Leblanc T et al (2016) Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol 3:e537–e546CrossRefPubMedGoogle Scholar
  17. 17.
    Reese JA, Muthurajah DS, Kremer Hovinga JA et al (2013) Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer 60:1676–1682CrossRefPubMedGoogle Scholar
  18. 18.
    Joly BS, Vanhoorelbeke K, Veyradier A (2017) Understanding therapeutic targets in thrombotic thrombocytopenic purpura. Intensive Care Med.  https://doi.org/10.1007/s00134-016-4662-3 PubMedCrossRefGoogle Scholar
  19. 19.
    Scully M, Knöbl P, Kentouche K et al (2017) Recombinant human ADAMTS-13: first in human study evaluating pharmacokinetics, safety and tolerability in cTTP patients. Blood 130:2055–2063CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature and ESICM 2018

Authors and Affiliations

  • Bérangère S. Joly
    • 1
    • 2
  • X. Long Zheng
    • 3
  • Agnès Veyradier
    • 1
    • 2
    Email author
  1. 1.Service d’hématologie biologique and EA3518-Institut universitaire d’hématologie, Groupe Hospitalier Saint Louis-Lariboisière Assistance Publique – Hôpitaux de ParisUniversité Paris DiderotParisFrance
  2. 2.French National Reference Centre for Thrombotic MicroAngiopathiesAssistance Publique – Hôpitaux de ParisParisFrance
  3. 3.Division of Laboratory Medicine, Department of PathologyThe University of Alabama at BirminghamBirminghamUSA

Personalised recommendations